KIT Mutation Detection in Sarcomas (Sequencing)
To detect mutations in the KIT receptor tyrosine kinase, which are commonly present in gastrointestinal stromal tumors (70-80% of all cases). Mutations in KIT can be used to identify patients that may respond to tyrosine kinase inhibitors, as well as patients that acquire secondary mutations and develop resistance to therapy.
This test is performed by PCR-based Sanger sequencing of DNA to examine the mutation status of exons 9, 11, 13 and 17 of KIT.
This assay will detect mutations present in exons 9, 11, 13 and 17 of KIT. The sensitivity of the Sanger sequencing assay is 20% of variant sequence in the background of wild-type sequence.
• 10 ug of purified DNA, sent on dry ice
• Four to six unstained recut slides of formalin-fixed, paraffin embedded tissue containing adequate amounts of tumor to be analyzed (See Sensitivity.)
The area of tumor to be analyzed should be indicated by circling the area on the bottom side of the slide or in a separate H&E-stained guide section.
Please provide a copy of the corresponding pathology report.
Additional charges may apply for tissue extraction.
The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.